Innoviva (INVA) Free Cash Flow Growth (1y) (2011 - 2026)
Innoviva (INVA) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | -28.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.44% |
| Sep 30, 2025 | 9.38% |
| Jun 30, 2025 | 0.81% |
| Mar 31, 2025 | 31.23% |
| Sep 30, 2024 | 20.11% |
| Jun 30, 2024 | 14.50% |
| Mar 31, 2024 | 44.43% |
| Sep 30, 2023 | -44.22% |
| Jun 30, 2023 | -51.68% |
| Mar 31, 2023 | -73.85% |
| Sep 30, 2022 | -27.37% |
| Jun 30, 2022 | -6.61% |
| Mar 31, 2022 | 16.63% |
| Sep 30, 2021 | 256.01% |
| Jun 30, 2021 | 6.04% |
| Mar 31, 2021 | 14.48% |
| Dec 31, 2020 | 27.49% |
| Sep 30, 2020 | 29.89% |
| Jun 30, 2020 | 41.24% |
| Mar 31, 2020 | -4.16% |